 Myeloma Proteins
"Myeloma Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.
| Descriptor ID |
D009194
|
| MeSH Number(s) |
D12.776.124.486.485.900.500 D12.776.124.790.651.900.500 D12.776.377.715.548.900.500 D12.776.624.553
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Myeloma Proteins".
Below are MeSH descriptors whose meaning is more specific than "Myeloma Proteins".
This graph shows the total number of publications written about "Myeloma Proteins" by people in this website by year, and whether "Myeloma Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Myeloma Proteins" by people in Profiles.
-
Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 10 16; 10(10):102.
-
Campbell JP, Heaney JLJ, Pandya S, Afzal Z, Kaiser M, Owen R, Child JA, Cairns DA, Gregory W, Morgan GJ, Jackson GH, Bunce CM, Drayson MT. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. Lancet Haematol. 2017 Dec; 4(12):e584-e594.
-
Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, Sparano JA. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011 Jan 15; 117(2):336-42.
-
Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S, Ely S, Mazumdar M, Cesarman E, Leonard JP, Furman RR, Chen-Kiang S, Niesvizky R. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol. 2008 Dec; 143(5):654-60.
-
Morstyn G, Schechter GP, Ihde DC, Carney DN, Eddy JL, Cohen MH, Minna JD, Bunn PA. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. Cancer Treat Rep. 1984 Dec; 68(12):1439-46.
-
Vignaux F, Stanislawski M, Gresser I. Inhibitory effect of interferon on myeloma in mice. Ann Immunol (Paris). 1984 Mar-Apr; 135C(2):187-94.
-
Pène J, Bekkhoucha F, Desaymard C, Zaghouani H, Stanislawski M. Induction of a cross-reactive idiotype dextran-positive antibody response in two IgH-Cb mouse strains treated with anti-J558 cross-reactive idiotype antibodies. J Exp Med. 1983 May 01; 157(5):1573-93.
-
Pène J, Zaghouani H, Stanislawski M. Regulation of the response to alpha 1-3 dextran in IghCb mice. Ann N Y Acad Sci. 1983; 418:296-304.
-
Stanislawski M, Mitard M, Harel A. An assay for the quantitative inhibition of anti-immunoglobulin antibodies performed at the cell surface. Studies with anti-kappa and anti-mu chain antibodies. Mol Immunol. 1979 May; 16(5):317-26.
-
Stanislawski M, Mitard M. Expression of immunoglobulin variable region antigens on mouse B lymphocytes. J Immunol. 1979 Mar; 122(3):1045-53.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|